全文获取类型
收费全文 | 97064篇 |
免费 | 7981篇 |
国内免费 | 2113篇 |
专业分类
耳鼻咽喉 | 951篇 |
儿科学 | 2150篇 |
妇产科学 | 1344篇 |
基础医学 | 4231篇 |
口腔科学 | 4846篇 |
临床医学 | 9183篇 |
内科学 | 11490篇 |
皮肤病学 | 1632篇 |
神经病学 | 5589篇 |
特种医学 | 2381篇 |
外国民族医学 | 23篇 |
外科学 | 13467篇 |
综合类 | 16933篇 |
现状与发展 | 11篇 |
一般理论 | 4篇 |
预防医学 | 6485篇 |
眼科学 | 1635篇 |
药学 | 8921篇 |
185篇 | |
中国医学 | 8985篇 |
肿瘤学 | 6712篇 |
出版年
2024年 | 289篇 |
2023年 | 1694篇 |
2022年 | 2888篇 |
2021年 | 4194篇 |
2020年 | 4488篇 |
2019年 | 3515篇 |
2018年 | 3320篇 |
2017年 | 3556篇 |
2016年 | 3900篇 |
2015年 | 3638篇 |
2014年 | 7085篇 |
2013年 | 9084篇 |
2012年 | 6628篇 |
2011年 | 6978篇 |
2010年 | 5808篇 |
2009年 | 5013篇 |
2008年 | 4429篇 |
2007年 | 4576篇 |
2006年 | 4040篇 |
2005年 | 3431篇 |
2004年 | 2860篇 |
2003年 | 2446篇 |
2002年 | 2011篇 |
2001年 | 1631篇 |
2000年 | 1388篇 |
1999年 | 1072篇 |
1998年 | 891篇 |
1997年 | 794篇 |
1996年 | 659篇 |
1995年 | 586篇 |
1994年 | 544篇 |
1993年 | 455篇 |
1992年 | 384篇 |
1991年 | 334篇 |
1990年 | 248篇 |
1989年 | 254篇 |
1988年 | 231篇 |
1987年 | 217篇 |
1986年 | 200篇 |
1985年 | 248篇 |
1984年 | 194篇 |
1983年 | 134篇 |
1982年 | 174篇 |
1981年 | 135篇 |
1980年 | 121篇 |
1979年 | 112篇 |
1978年 | 62篇 |
1977年 | 58篇 |
1976年 | 46篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
21.
22.
《Clinical gastroenterology and hepatology》2022,20(3):e380-e397
- Download : Download high-res image (232KB)
- Download : Download full-size image
23.
《Actas urologicas espa?olas》2022,46(9):550-556
ObjectiveProstate cancer (PCa) is the second most common solid tumor in men and the fifth leading cause of cancer-related death. In advanced stage, palliative treatments are used instead of curative therapies. Therefore, finding predictive indicators seems crucial. Patients with castration-resistant prostate cancer (CRPC) that received Dx chemotherapy have been retrospectively reviewed. The aim of this study was to investigate whether docetaxel (Dx)-free interval could have a predictive value for PCa and influence other sequential therapies.Material and methodsThis clinical trial study was performed on 104 patients at Medeniyet University Oncology Clinic in 2018-2020. All CRPC patients had metastases, received Dx as first-line treatment and underwent androgen receptor axis targeted (ARAT) therapy after disease progression. We analyzed patients’ progression time after Dx therapy and the effects on sequential treatment.ResultsAfter Dx therapy, all patients received ARAT (abiraterone (ABI) n: 49 (47.1%) and enzalutamide (ENZ) n: 54 (51.9%)) as a second-line treatment, except for one patient who received cabazitaxel. There was a statistically significant relationship between the Dx-free interval and duration of response to ARAT (P<.001). The response time of ARAT treatment was <10.5 months in all patients whose Dx-free interval period was <9 months.ConclusionsOur findings support the theory that Dx-free interval can be a predictive factor for CRPC. CRPC disease can be classified as Dx-sensitive disease or Dx-resistance disease, based on the Dx-free interval. Decision on subsequent treatments could be made considering this information. 相似文献
24.
25.
《Vaccine》2020,38(3):570-577
IntroductionPediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs).MethodsIn a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped.ResultsS. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1–4.3 years] vs. median 5.6 years [IQR 3.8–8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1.ConclusionFollowing the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3. 相似文献
26.
27.
28.
29.
����һ���� Ȫ 《中国实用外科杂志》2019,39(3):223-225
妊娠期甲状腺癌的诊治是目前甲状腺疾病诊治的热点和难点问题之一。妊娠期发现甲状腺癌对临床医生和孕妇都是一个极大的挑战,应通过多学科协作,尽快明确诊断,全面、合理的评估孕妇和胎儿的情况,选择最合适的治疗和随诊方式,避免对孕妇和胎儿产生副反应,维持正常孕期,获得最佳的治疗效果。 相似文献
30.
肺癌是世界上发病率最高的恶性肿瘤之一,外科手术为首选治疗方式。近年来许多新兴微创技术治疗肺癌取得了良好效果。氩氦冷冻消融术因具有损伤小、恢复快、安全性高、并发症少等优点,已取得医患双方认可。冷冻消融适用于不能手术切除的早期肺癌及减少晚期肺癌负荷。肿瘤是一种全身性疾病,因此冷冻消融联合其他治疗方法将是未来肺癌治疗发展方向,从而改善患者临床症状,提高生活质量,延长生存时间,达到最佳治疗效果。该文就冷冻消融治疗及与其他方法综合治疗肺癌研究现状和进展作一综述。 相似文献